Clinical trials: Solid Tumor (Phase I)
Breast Neoplasm, Colon Neoplasm
A Study of MLN8054 in Patients With Advanced Solid Tumors
The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and…
- Conditions
- Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
- Trial name
- NCT00249301
- Testing
- MLN8054
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize…
- Trial name
- NCT01980667
- Testing
- lurbinectedin (PM01183), Cisplatin
- Where
- 3 sites in Switzerland, United Kingdom
- Volunteers
- 41 people
- Sponsor
- PharmaMar
Solid Tumors
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
The study evaluates safety of adavosertib in monotherapy, and in combination with 5-Fluorouracil (5-FU) alone or with 5-FU/cis-diamminedichloroplatinum (CDDP) in Japanese participants with solid tumor.
- Trial name
- NCT01047007
- Testing
- adavosertib 20 mg, 5-FU 1000 mg/m^2/day, CDDP
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung…
- Trial name
- NCT01928394
- Testing
- Nivolumab, Ipilimumab, Cobimetinib
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 1,163 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD)…
- Trial name
- NCT04891653
- Testing
- BR790
- Volunteers
- 48 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Metastatic Cancer, Solid Tumor
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03311412
- Testing
- Sym021, Sym022, Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 89 people
- Sponsor
- Symphogen A/S
Solid Tumor
QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
The purpose of this study is to determine whether haNK™ for Infusion is safe and effective in the treatment of metastatic or locally advanced solid tumors.
- Trial name
- NCT03027128
- Testing
- haNK™ for Infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Tumors, Breast
Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery
Surgery is the primary treatment modality for many types of cancer and the extent of surgical resection is directly related to patient survival.
- Trial name
- NCT02496065
- Testing
- BLZ-100
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Blaze Bioscience Inc.
Advanced Malignant Solid Tumors
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
This open, dose-escalation and extended PhI/IIa clinical trial aims to evaluate the safety, tolerability of T601 as a single-agent as well as combined with prodrug 5-FC to treat patients with advanced malignant solid tumors and…
- Trial name
- NCT04226066
- Testing
- T601, T601+5-FC
- Where
- 2 sites in China
- Volunteers
- 69 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Cancer
A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose of ALB 109564(a), a novel tubulin inhibitor, and to assess safety, pharmacokinetics, and anti-tumor activity in subjects with advanced solid tumors.
- Trial name
- NCT00724100
- Testing
- ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Albany Molecular Research, Inc.
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Neoplasm Malignant
A Study of PSB205 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, Phase 1, ascending dose escalation study of PSB205 in subjects with advanced solid tumors. The study will be conducted in 2 parts.
- Trial name
- NCT03986606
- Testing
- PSB205
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Advanced CEACAM6-expressing Solid Tumors
Study of BAY1834942 in Patients With Solid Tumors
This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the…
- Trial name
- NCT03596372
- Testing
- BAY1834942
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Bayer
Solid Tumors
Kanitinib in Treating Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.
- Trial name
- NCT02916095
- Testing
- Kanitinib
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT04842630
- Testing
- SHR-1916
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.
- Trial name
- NCT06925581
- Testing
- HRS-6768
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasms
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
- Trial name
- NCT00528619
- Testing
- Sunitinib, Pemetrexed, Cisplatin, Carboplatin
- Where
- 3 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- Pfizer